When is tucatinib/tucatinib expected to be launched in China?

Tucatinib/Tucatinib is an innovative drug that has attracted much attention recently. It has achieved impressive results in the treatment of HER2+ advanced breast cancer complicated by brain metastases. Unfortunately, as of mid-April 2024, this drug has not yet been officially launched in the Chinese market. Any new drug launched in China must undergo strict approval by the State Food and Drug Administration. It is hoped that this revolutionary drug will be approved by Chinese regulatory authorities in the near future, thus bringing new treatment options and hope to more patients with HER2+ advanced breast cancer.

In an ambitious, randomized, double-blind, placebo-controlled clinical trial, researchers found that combining tucatinib with trastuzumab and capecitabine can produce significant clinical responses in up to60% of patients with refractory, metastatic, or advanced inoperable HER2-positive breast cancer, including those who have developed brain metastases. For this reason, the treatment regimen of tucatinib combined with trastuzumab and capecitabine was approved by the U.S. Food and Drug Administration (FDA) in 2020 for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer after the failure of previous anti-HER2-based treatment regimens.

It is worth mentioning that, unlike traditional monoclonal antibodies, tucatinib has the ability to cross the blood-brain barrier, which may be why it performs well in treating brain metastases that are difficult to treat with anti-HER2 monoclonal antibodies. By 2023, the therapeutic indications of tucatinib will be further expanded, and it will be used in combination with trastuzumab to treat refractory HER2-positive advanced inoperable metastatic colorectal cancer.